High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients

被引:0
作者
Jian-Cong Sun
机构
基金
中国国家自然科学基金;
关键词
Epidermal growth factor-like repeats and discoidin I-like domains 3; Hepatocellular carcinoma; Prognosis; Angiogenesis;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
AIM:To determine the role of epidermal growth factor-like repeats and discoidin I-like domains 3(EDIL3)in pathogenesis of hepatocellular carcinoma(HCC)by investigating the EDIL3 expression in HCC and its prognostic value for HCC.METHODS:EDIL3 expression was detected in 101 HCC surgical tissue samples with immunohistochemistry method,and its relation with clinicopathologic features and prognosis of HCC patients was analyzed.RESULTS:EDIL3 was highly expressed in 48.5%of the HCC patients.Although the EDIL3 expression level did not correlate with any clinicopathological parameters,KaplanMeier survival analysis showed that high expression level of EDIL3 resulted in a significantly poor prognosis of HCC patients(log-rank test,P=0.010).Multivariate Cox’s analysis showed that the EDIL3 expression level was a significant and independent prognostic parameter for the overall survival rate of HCC patients(hazard ratio=1.978,95%confidence interval =1.139-3.435,P=0.015).CONCLUSION:High expression level of EDIL3 pre-dicts poor prognosis of HCC patients.EDIL3 may be a potential target of antiangiogenic therapy for HCC.
引用
收藏
页码:4611 / 4615
页数:5
相关论文
共 7 条
  • [1] Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009[J] . Donald Poon,Benjamin O Anderson,Li-Tzong Chen,Koichi Tanaka,Wan Yee Lau,Eric Van Cutsem,Harjit Singh,Wan Cheng Chow,London Lucien Ooi,Pierce Chow,Maung Win Khin,Wen Hsin Koo.Lancet Oncology . 2009 (11)
  • [2] Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease[J] . Paul Michael Grossman,Farrell Mendelsohn,Timothy D. Henry,James B. Hermiller,Marc Litt,Jorge F. Saucedo,Robert J. Weiss,David E. Kandzari,Neal Kleiman,R. David Anderson,Daniel Gottlieb,Ronald Karlsberg,Jeffery Snell,Krishna Rocha-Singh.American Heart Journal . 2007 (5)
  • [3] Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma
    Pang, Roberta
    Poon, Ronnie T. P.
    [J]. CANCER LETTERS, 2006, 242 (02) : 151 - 167
  • [4] Anti-apoptotic effects of the angiogenic factor Del1 on endothelial cells[J] . Z. Wang,M.T. Longaker,G.P. Yang.Journal of Surgical Research . 2006 (2)
  • [5] The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation
    Aoka, Y
    Johnson, FL
    Penta, K
    Hirata, K
    Hidai, C
    Schatzman, R
    Varner, JA
    Quertermous, T
    [J]. MICROVASCULAR RESEARCH, 2002, 64 (01) : 148 - 161
  • [6] Microvessel density of hepatocellular carcinoma: its relationship with prognosis[J] . Hui-Chuan Sun,Zhao-You Tang,Xiao-Ming Li,Yan-Nan Zhou,Bao-Rong Sun,Zeng-Chen Ma.Journal of Cancer Research and Clinical Oncology . 1999 (7)
  • [7] Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma[J] . Akitaka Yamamoto,Dipok Kumar Dhar,Osama Nazmy El-Assal,Igarashi Masahiko,Tabara Hideki,Nagasue Naofumi.Journal of Hepatology . 1998 (2)